Pharmaxis Cash Flow - Quarterly (OTCMKTS:PXSLY)

Add to My Stocks
$3.95 $0 (0%) PXSLY stock closing price Sep 17, 2018 (Closing)

The Pharmaxis cash flow statement helps investors understand how well the company is managing its cash flows. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Pharmaxis profits one has to check the income statement and for Pharmaxis debt one has to check the balance sheet. Pharmaxis cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Pharmaxis had cash and cash equivalents of $58.71M at the beginning of the quarter and $16.21M at quarter end for 2017 Q4. The cash from operating activities for Pharmaxis is $ 2017 Q4, which saw a decrease from previous quarter.

View and download details of Pharmaxis cash flows for latest & last 40 quarters
show more
Fiscal year is Jul - Jun2017 Q42016 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow2.3M2.33M
Net Increase (Decrease) in Assets Liabilities-0.47M1.34M
Cash From (used in) Discontinued Operations--
Other Adjustments Net--0.41M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.23M-0.99M
Acquisition Disposition of Subsidiaires--
Increase (Decrease) in Investments--
Other Cash Inflow (Outflow) from Investment Activities-0.3M-0.01M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares--
Issuance (Repayment) of Debt Securities-1.12M-1.05M
Increase (Decrease) in Bank & Other Borrowings--
Payment of Dividends & Other Cash Distributions--
Other Cash from (used by) Financing Activities-0.17M-0.19M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash--
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year58.71M110.26M
Cash & Equivalents at Year End16.21M28.56M
All figures in USD. M: Millions of USD, B: Billions of USD.

Pharmaxis stock price history provides insight into historical stock price fluctuations, and Pharmaxis stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Pharmaxis had a Net Change in Cash and Cash Equivalents of $-13.34M in the latest quarter 2017 Q4. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Pharmaxis stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Pharmaxis reported a negative operating cash flow of $-11.5M till 2017 Q4 and has seen a decrease from the previous quarter. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-0.54M for PXSLY till last quarter 2017 Q4 report.
  • Cash flow from financing activities shows the flow of cash between Pharmaxis and its owners and creditors and was $-1.29M till 2017 Q4. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Pharmaxis Cash Flow